Avadel Pharmaceuticals Strengthens Sleep Medicine Portfolio with Exclusive License of Valiloxybate from XWPharma Ltd
Expands Avadel’s pipeline with salt-free, artificial sweetener-free, once-at-bedtime oxybate for treatment of narcolepsy and idiopathic hypersomnia. XWPharma to receive $20 million upfront; potential for development, regulatory and sales milestone payments in addition to royalties on future net sales
Article Date
September 3, 2025
This article is featured on another website.
Go to article
July 31, 2026
What Makes a Modern CRO? Inside HiRO’s Global Growth Story
Part 1 of 5 in our series: What Makes a Modern CRO? Inside HiRO's Global…
July 31, 2026
What Makes a Modern CRO? Inside HiRO’s Global Growth Story
Part 1 of 5 in our series: What Makes a Modern CRO? Inside HiRO's Global…
July 15, 2026
Glioblastoma Clinical Trials – Where Progress is Actually Happening in Glioma Research
Where Glioma Research Is Actually Moving Forward Glioblastoma (GBM) is the most common and most…
July 15, 2026
Glioblastoma Clinical Trials – Where Progress is Actually Happening in Glioma Research
Where Glioma Research Is Actually Moving Forward Glioblastoma (GBM) is the most common and most…